ProfileGDS5678 / 1438574_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 56% 47% 46% 48% 50% 47% 47% 47% 47% 46% 45% 47% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1903448
GSM967853U87-EV human glioblastoma xenograft - Control 23.4038156
GSM967854U87-EV human glioblastoma xenograft - Control 33.1141147
GSM967855U87-EV human glioblastoma xenograft - Control 43.0102846
GSM967856U87-EV human glioblastoma xenograft - Control 53.097748
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2903850
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1836647
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0988247
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.08447
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1026747
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0671246
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0034245
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1031847
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1027847